Author:
Jurado‐Palomo Jesús,Caballero Teresa
Reference74 articles.
1. Caballero T, Baeza ML, Cabañas R, Campos A, Cimbollek S, Gómez‐Traseira C, et al. Consensus statement on the diagnosis, management, and treatment of angioedema mediated by bradykinin. Part I. Classification, epidemiology, pathophysiology, genetics, clinical symptoms, and diagnosis. J Investig Allergol Clin Immunol. 2011;21:333–47; quiz follow 347. Review. Erratum in: J Investig Allergol Clin Immunol. 2012;22:3 p following 153.
2. Roche O, Blanch A, Caballero T, Sastre N, Callejo D, López‐Trascasa M. Hereditary angioedema due to C1 inhibitor deficiency: patient registry and approach to the prevalence in Spain. Ann Allergy Asthma Immunol. 2005;94:498–503.
3. Bygum A. Hereditary angio‐oedema in Denmark. A nationwide survey. Br J Dermatol 2009;161:1153–8.
4. Zanichelli A, Arcoleo F, Barca MP, Borrelli P, Bova M, Cancian M, et al. A nationwide survey of hereditary angioedema due to C1 inhibitor deficiency in Italy. Orphanet J Rare Dis. 2015;10:11.
5. Stray‐Pedersen A, Abrahamsen TG, Frøland SS. Primary immunodeficiency diseases in Norway. J Clin Immunol. 2000;20:477–85.